Welcome to our dedicated page for CEL SCI SEC filings (Ticker: CVM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CEL-SCI Corporation filings document a clinical-stage biotechnology issuer funding the development of Multikine through registered securities offerings and reporting material corporate actions. Registration statements and prospectus-related filings describe common stock issuance capacity, use of proceeds for Multikine development, working capital, risk factors, operating and financial results, and the company's capital structure.
Current reports on Form 8-K record placement agency agreements, closed equity offerings, and amendments to the company's Shareholder Rights Agreement, including modifications to security-holder rights. The filing record also provides formal disclosure around governance, material agreements, and financing terms tied to CEL-SCI's cancer immunotherapy development business.
Cel-Sci Corp. (CVM) Form 4 filing discloses that Chief Executive Officer and Director Geert R. Kersten purchased 2,292 shares of common stock on 06/30/2025 at a price of $2.29 per share. Following the transaction, Kersten directly holds 43,638 shares. No derivative security activity was reported. The filing was signed on 07/01/2025 and represents a single-person submission under Section 16 reporting requirements.